Different Postoperative Analgesics Use After Ureteroscopy

Post Operative Pain Clinical Trial

Official title:

Effectiveness of Different Postoperative Analgesics Use in the Management of Acute Pain After Ureteroscopy.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05507554
• Other study ID #: PKLI Nadeem Iqbal
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2022
• Est. completion date: December 2022

Study information

• Verified date: August 2022
• Source: Pakistan Kidney and Liver Institute and Research Center
• Contact: Nadeem Iqbal, FCPS*
• Phone: +92 3345346538
• Email: dr_nadeemiqbal84[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, we will see the feasibility of a non-opioid pain killers in management of acute post-operative period as well as on discharge from the hospital compared to opioid medications for postoperative pain following URS and stent placement.

The objective of this study will be to compare the pain control effects of no opioid and opioid pain killers during the post-operative period. This study will be a Randomized Clinical trial. Data will be collected from department of Urology, PKLI, Lahore. All patients included in this study will undergo ureteroscopic laser lithotripsy of ureter stones. One group will receive tramadol (opioid) while other two groups will receive Paracetamol and diclofenac sodium (NSAIDs) respectively. All subjects will receive one of the three pain killers after ureteroscopy procedure for ureter stones in a randomized fashion. Postoperative pain intensity will be measured by the investigator and the nurse in the first hour after the surgery in the recovery room and then in urology ward at 1,6, 12, 24, 48, & 72 hours using the Numeric Pain Intensity Scale (NPIS).A mean pain score of less than 2 for each category of surgical procedures or analgesics group will be defined as satisfactory pain control. The data will be analyzed using SPSS v 24.

Description:

Achieving adequate postoperative pain relief should be a definitive goal of patient care in any surgery because pain is one of the most common postoperative symptoms as reported from previous studies. Efforts have begun to implement non opioid protocols for outpatient urologic surgery. Recently it was found that Ureteroscopy (URS) with stent placement is possible without using postoperatve opioids for pain control and stent-related symptoms. To date, attention has focused on the problems of opioid abuse, diversion, and overdose. These issues pertain primarily to those who are already suffering from substance use disorders. More recently, the possibility that legitimate use of prescription opioids has led to incident substance use disorders (iatrogenic addiction) is beginning to gather attention.

When iatrogenic addiction has been considered, it is almost exclusively in the context of chronic pain. Not surprisingly, emergency providers commonly believe that short courses of opioid therapy for acute pain are safe and that their role in the current opioid crisis is limited to attenuating diversion. However, several recent studies have demonstrated that short course opioid therapy for acute pain is associated with future recurrent use of opioids, raising the possibility that short course opioid therapy may be a potential trigger for the onset of opioid related substance use disorders. If so, there are considerable health implications as more than 1 in every 6 patients discharged from an ED are given a prescription for an opioid pain reliever.

In this study, we will see the feasibility of a non-opioid discharge protocol compared to standard opioid medications for postoperative pain following URS and stent placement. We will also evaluate the effect of these analgesic in acute pain management in post op stay in hospital.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 176
• Est. completion date: December 2022
• Est. primary completion date: October 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Ureteroscopy procedure performed for ureteric stones between age 18 -60 years.

2. Patients with normal Renal and Liver function tests function tests.

3. Patients having no growth on urine culture will be included in this study.

4. Patients with no previous history of ureteroscopy procedure in past.

Exclusion Criteria:

1. Patients having history of allergic reaction to any type of the drugs to be used in the study.

2. If Paracetamol contraindicated in severe hepatic impairment, or severe active hepatic disease.

3. If Diclofenac contraindicated in compromised renal function, increased risk of bleeding due to clotting disorder, an increased risk of bleeding, gastric ulcers, alcoholism.

4. If tramadol is contraindicated as in alcoholism, depression and drug abuse.

5. When a patient has a history of opioid abuse.

6. When a patient refuses to participate in the study.

7. When patient is unable to give consent.

8. Pregnancy.

9. If the patient has used conventional NSAIDs, Acetaminophen or Tramadol during the 6 hours before surgery,

Related Conditions & MeSH terms

• Pain, Postoperative
• Post Operative Pain
• Ureter Stone
• Ureteroscopy

Intervention

Drug:
• Opioid
Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally. Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later.
• Non-Opioid Analgesic
Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally. Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later.
• Non-Opioid
Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally. Designated coated 14 days supply of pain medication (oral Tablet Diclofenac Sodium 50 mg) will be given to the patients on discharge. For Pain control oral Diclofenac Sodium 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later.

Locations

Country	Name	City	State
Pakistan	Pakistan Kidney and Liver Institute	Lahore	Punjab

Sponsors (1)

Lead Sponsor	Collaborator
Pakistan Kidney and Liver Institute and Research Center

Country where clinical trial is conducted

Pakistan, 

References & Publications (5)

Kang C, Shu X, Herrell SD, Miller NL, Hsi RS. Opiate Exposure and Predictors of Increased Opiate Use After Ureteroscopy. J Endourol. 2019 Jun;33(6):480-485. doi: 10.1089/end.2018.0796. Epub 2019 Feb 8. — View Citation

Kasman AM, Schmidt B, Spradling K, Chow C, Hunt R, Wu M, Sockol A, Liao J, Leppert JT, Shah J, Conti SL. Postoperative opioid-free ureteroscopy discharge: A quality initiative pilot protocol. Curr Urol. 2021 Sep;15(3):176-180. doi: 10.1097/CU9.0000000000000025. Epub 2021 May 26. — View Citation

Klueh MP, Hu HM, Howard RA, Vu JV, Harbaugh CM, Lagisetty PA, Brummett CM, Englesbe MJ, Waljee JF, Lee JS. Transitions of Care for Postoperative Opioid Prescribing in Previously Opioid-Naïve Patients in the USA: a Retrospective Review. J Gen Intern Med. 2018 Oct;33(10):1685-1691. doi: 10.1007/s11606-018-4463-1. Epub 2018 Jun 11. — View Citation

Salaudeen GO, Afuwape OO, Eyelade OR, Olapade-Olaopa EO. Effectiveness of postoperative analgesia in the management of acute pain in day-case surgeries. Ann Afr Med. 2018 Jul-Sep;17(3):140-144. doi: 10.4103/aam.aam_53_17. — View Citation

Tam CA, Dauw CA, Ghani KR, Gunaseelan V, Kim T, Leavitt DA, Raisky J, Yan PL, Hollingsworth JM. New Persistent Opioid Use After Outpatient Ureteroscopy for Upper Tract Stone Treatment. Urology. 2019 Dec;134:103-108. doi: 10.1016/j.urology.2019.08.042. Epub 2019 Sep 16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain score in post op period at 1 hour.	Pain score assessment at one hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.	[1 hour]
Primary	Pain score in post op period at 6 hour.	Pain score assessment at six hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.	[6 hour]
Primary	Pain score in post op period at 12 hour.	Pain score assessment at twelve hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.	[12 hour]
Primary	Pain score in post op period at 24 hour.	Pain score assessment at twenty four hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.	[24 hour]
Primary	Pain score in post op period at 48 hour.	Pain score assessment at forty eight hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.	[48 hour]
Primary	Pain score in post op period at 72 hour.	Pain score assessment at seventy two hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.	[72 hour]
Secondary	Patient Satisfaction	Score on standardized evaluation of patient satisfaction at 7-days post-op. This was on a scale from 1) very dissatisfied to 5) very satisfied. Higher scores are better	First 30 post-operative days
Secondary	4. Emergency visit for pain symptoms by the patients in the postoperative period after the discharge	Number of times patients visited health facility for pain exacerbation	First 30 post-operative days
Secondary	Hospital pain killers refill visits of patients for each category of analgesic used	Number of times patients visited health facility for refill pain killers medication	30 post-operative days